RGENNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
REPLIGEN CORP
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026
$176.43+1.01 (+0.58%)
Close on Oct 19, 2026
- Market cap
- $9.99B
- P/E (TTM)
- 205.2
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
100.0%
66M of 56M shares
Institutional holders
480
98 new, 56 sold out
Net institutional buying
1M
In Q2 2026
Insider trades, 12 months
0 buys · 23 sales
Net sold $14.23M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| FMR LLC | 7,361,318 | 13.00% | 13G (passive) amendment | Sep 30, 2026 |
| BlackRock, Inc. | 5,198,107 | 9.30% | 13G (passive) amendment | Mar 31, 2025 |
| Vanguard Capital Management | 2,825,579 | 5.00% | 13G (passive) | Jun 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of RGEN | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 5,384,938 | 9.54% | $734.72M | −608,116 | 0.01% |
| FMR LLC | 3,326,690 | 5.89% | $453.89M | +439,904 | 0.02% |
| United Capital Financial Advisers, LLC | 2,790,650 | 4.94% | $380.76M | +16,670 | 2.10% |
| Vanguard Capital Management LLC | 2,411,171 | 4.27% | $328.98M | +14,660 | 0.01% |
| Vanguard Portfolio Management LLC | 2,312,825 | 4.10% | $315.56M | +7,731 | 0.01% |
| Maverick Capital Ltd | 1,984,554 | 3.52% | $270.77M | +465,749 | 2.39% |
| State Street Corp | 1,800,530 | 3.19% | $245.68M | +23,245 | 0.01% |
| Price T Rowe Associates Inc /Md/ | 1,752,274 | 3.10% | $239.08K | −3,125,867 | 0.02% |
| Massachusetts Financial Services Co /Ma/ | 1,617,021 | 2.87% | $220.61M | +219,506 | 0.07% |
| Wasatch Advisors LP | 1,590,251 | 2.82% | $216.97M | +346,720 | 1.42% |
| Ameriprise Financial Inc | 1,576,132 | 2.79% | $215.05M | +650,918 | 0.04% |
| Bank of New York Mellon Corp | 1,522,859 | 2.70% | $207.78M | −8,543 | 0.03% |
| T. Rowe Price Investment Management, Inc. | 1,411,619 | 2.50% | $192.60K | +44,939 | 0.13% |
| Invesco Ltd. | 1,387,242 | 2.46% | $189.28M | +108,987 | 0.01% |
| Holocene Advisors, LP | 1,292,191 | 2.29% | $176.31M | +583,302 | 0.40% |
| Rtw Investments, LP | 1,240,637 | 2.20% | $169.27M | +34,637 | 1.45% |
| Geode Capital Management, LLC | 1,062,476 | 1.88% | $145.00M | −1,981 | 0.01% |
| Congress Asset Management Co /Ma | 1,012,226 | 1.79% | $138.11M | +214,359 | 0.85% |
| Conestoga Capital Advisors, LLC | 980,983 | 1.74% | $133.85M | −116,800 | 2.91% |
| Goldman Sachs Group Inc | 965,411 | 1.71% | $131.72M | +314,064 | 0.01% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 480 | 66M | 100.0% | 98 / 174 | 143 / 56 | 10M | 9M |
| Q1 2026 | 445 | 66M | 100.0% | 69 / 166 | 131 / 92 | 15M | 6M |
| Q4 2025 | 475 | 62M | 100.0% | 96 / 152 | 143 / 62 | 10M | 8M |
| Q3 2025 | 453 | 60M | 100.0% | 80 / 159 | 151 / 65 | 12M | 10M |
| Q2 2025 | 444 | 59M | 100.0% | 74 / 129 | 174 / 69 | 7M | 6M |
| Q1 2025 | 441 | 58M | 100.0% | 61 / 172 | 129 / 45 | 5M | 3M |
| Q4 2024 | 431 | 56M | 99.6% | 60 / 136 | 159 / 67 | 5M | 5M |
| Q3 2024 | 445 | 56M | 99.0% | 74 / 157 | 157 / 81 | 14M | 6M |
| Q2 2024 | 455 | 56M | 99.8% | 66 / 160 | 165 / 92 | 6M | 8M |
| Q1 2024 | 486 | 58M | 100.0% | 61 / 173 | 168 / 36 | 3M | 5M |
| Q4 2023 | 467 | 59M | 100.0% | 77 / 154 | 160 / 44 | 5M | 3M |
| Q3 2023 | 440 | 57M | 100.0% | 56 / 164 | 156 / 61 | 5M | 3M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of RGEN | Value | % of fund | As of |
|---|---|---|---|---|---|
| iShares Core S&P Mid-Cap ETF | 1,814,742 | 3.22% | $247.60M | 0.20% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 1,702,844 | 3.02% | $232.34M | 0.01% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 1,229,445 | 2.18% | $167.75M | 0.09% | Jun 30, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 963,028 | 1.71% | $131.40M | 0.89% | Jun 30, 2026 |
| MFS Mid Cap Growth Fund | 862,365 | 1.53% | $106.89M | 0.78% | May 31, 2026 |
| Vanguard Small-Cap Growth Index Fund | 709,041 | 1.26% | $96.74M | 0.21% | Jun 30, 2026 |
| Wasatch Core Growth Fund | 673,975 | 1.19% | $91.96M | 3.08% | Jun 30, 2026 |
| First Trust NYSE Arca Biotechnology Index Fund | 631,943 | 1.12% | $86.22M | 3.07% | Jun 30, 2026 |
| T. Rowe Price Small-Cap Stock Fund, Inc. | 619,174 | 1.10% | $84.48M | 0.91% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 608,541 | 1.08% | $83.03M | 0.08% | Jun 30, 2026 |
| Select Medical Technology and Devices Portfolio | 520,000 | 0.92% | $64.45M | 2.17% | May 31, 2026 |
| Columbia Small Cap Growth Fund | 508,986 | 0.90% | $63.09M | 1.72% | May 31, 2026 |
| Select Health Care Portfolio | 460,000 | 0.82% | $57.02M | 0.99% | May 31, 2026 |
| Conestoga Small Cap Fund | 431,645 | 0.76% | $58.89M | 2.88% | Jun 30, 2026 |
| Strategic Advisers Fidelity U.S. Total Stock Fund | 428,500 | 0.76% | $53.11M | 0.02% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Olivier Loeillot | Chief Executive Officer, Director | 48,369 | 0.09% | Sep 25, 2026 |
| Jason K. Garland | CFO | 18,408 | 0.03% | Sep 28, 2026 |
| Violetta Hughes | CHIEF ACCOUNTING OFFICER | 6,331 | 0.01% | Sep 2, 2026 |
| Brian Robb Douglass | CHIEF PRODUCT OFFICER | 7,985 | 0.01% | May 8, 2026 |
| Ralf Kuriyel | Senior VP, R&D | 20,062 | 0.04% | Mar 23, 2026 |
| James Bylund | Chief Operating Officer | 25,423 | 0.05% | Mar 23, 2026 |
| Nicolas Barthelemy | Director | 5,436 | 0.01% | May 18, 2026 |
| Manner Carrie Eglinton | Director | 5,461 | 0.01% | May 18, 2026 |
| Rohin Mhatre | Director | 5,014 | 0.01% | May 18, 2026 |
| Martin D. Madaus | Director | 8,392 | 0.01% | May 18, 2026 |
| Karen A. Dawes | Director | 92,816 | 0.16% | May 18, 2026 |
| Glenn P. Muir | Director | 40,051 | 0.07% | May 18, 2026 |
| Konstantin Konstantinov | Director | 3,889 | 0.01% | May 18, 2026 |
| Margaret Pax | Director | 3,011 | 0.01% | May 18, 2026 |
| Anthony Hunt | Director | 89,062 | 0.16% | Mar 3, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Jason K. Garland CFO | Sep 25, 2026 | Tax withholding | −421 | $189.68 | $79.86K | 18,408 |
| Olivier Loeillot Chief Executive Officer, Director | Sep 24, 2026 | Sale(10b5-1 plan) | −4,542 | $190.00 | $862.98K | 48,369 |
| Olivier Loeillot Chief Executive Officer, Director | Sep 24, 2026 | Option exercise | +4,542 | $155.38 | $705.74K | 52,911 |
| Olivier Loeillot Chief Executive Officer, Director | Sep 24, 2026 | Option exercise | +8,404 | $154.96 | $1.30M | 56,773 |
| Olivier Loeillot Chief Executive Officer, Director | Sep 24, 2026 | Sale(10b5-1 plan) | −8,404 | $190.00 | $1.60M | 48,369 |
| Olivier Loeillot Chief Executive Officer, Director | Sep 21, 2026 | Sale(10b5-1 plan) | −5,426 | $180.00 | $976.68K | 48,369 |
| Olivier Loeillot Chief Executive Officer, Director | Sep 21, 2026 | Option exercise | +5,426 | $141.79 | $769.35K | 53,795 |
| Olivier Loeillot Chief Executive Officer, Director | Sep 4, 2026 | Sale(10b5-1 plan) | −3,035 | $165.90 | $503.51K | 48,369 |
| Olivier Loeillot Chief Executive Officer, Director | Sep 3, 2026 | Tax withholding | −2,842 | $169.61 | $482.03K | 51,404 |
| Violetta Hughes CHIEF ACCOUNTING OFFICER | Sep 1, 2026 | Tax withholding | −277 | $170.02 | $47.10K | 6,331 |
| Olivier Loeillot Chief Executive Officer, Director | Aug 20, 2026 | Option exercise | +5,426 | $141.79 | $769.35K | 59,672 |
| Olivier Loeillot Chief Executive Officer, Director | Aug 20, 2026 | Sale(10b5-1 plan) | −5,426 | $180.00 | $976.68K | 54,246 |
| Jason K. Garland CFO | Jul 16, 2026 | Sale(10b5-1 plan) | −530 | $150.00 | $79.50K | 18,829 |
| Jason K. Garland CFO | Jun 25, 2026 | Sale(10b5-1 plan) | −733 | $145.00 | $106.29K | 19,359 |
| Karen A. Dawes Director | May 14, 2026 | Award | +995 | – | – | 92,816 |
| Rohin Mhatre Director | May 14, 2026 | Award | +995 | – | – | 5,014 |
| Konstantin Konstantinov Director | May 14, 2026 | Award | +995 | – | – | 3,889 |
| Manner Carrie Eglinton Director | May 14, 2026 | Award | +995 | – | – | 5,461 |
| Margaret Pax Director | May 14, 2026 | Award | +995 | – | – | 3,011 |
| Martin D. Madaus Director | May 14, 2026 | Award | +995 | – | – | 6,581 |
| Nicolas Barthelemy Director | May 14, 2026 | Award | +995 | – | – | 5,436 |
| Glenn P. Muir Director | May 14, 2026 | Award | +995 | – | – | 40,051 |
| Glenn P. Muir Director | May 7, 2026 | Option exercise | +2,434 | $38.76 | $94.34K | 39,056 |
| Brian Robb Douglass CHIEF PRODUCT OFFICER | May 7, 2026 | Tax withholding | −334 | $126.43 | $42.23K | 7,985 |
| Olivier Loeillot Chief Executive Officer, Director | Apr 21, 2026 | Sale(10b5-1 plan) | −3,832 | $140.00 | $536.48K | 54,246 |
| Violetta Hughes CHIEF ACCOUNTING OFFICER | Mar 5, 2026 | Award | +2,466 | – | – | 6,608 |
| Jason K. Garland CFO | Mar 5, 2026 | Award | +7,751 | – | – | 20,092 |
| Olivier Loeillot Chief Executive Officer | Mar 5, 2026 | Award | +24,134 | – | – | 58,078 |
| James Bylund Chief Operating Officer | Mar 5, 2026 | Award | +7,751 | – | – | 25,423 |
| Ralf Kuriyel Senior VP, R&D | Mar 5, 2026 | Award | +5,284 | – | – | 20,062 |
| James Bylund Chief Operating Officer | Mar 4, 2026 | Tax withholding | −62 | $125.84 | $7.80K | 17,672 |
| James Bylund Chief Operating Officer | Mar 4, 2026 | Award | +125 | – | – | 17,734 |
| Ralf Kuriyel Senior VP, R&D | Mar 4, 2026 | Tax withholding | −42 | $125.84 | $5.29K | 14,778 |
| Ralf Kuriyel Senior VP, R&D | Mar 4, 2026 | Award | +125 | – | – | 14,820 |
| Jason K. Garland CFO | Mar 2, 2026 | Tax withholding | −715 | $124.97 | $89.35K | 12,341 |
| Anthony Hunt Director | Mar 2, 2026 | Tax withholding | −9,897 | $124.97 | $1.24M | 89,062 |
| Brian Robb Douglass CHIEF PRODUCT OFFICER | Mar 2, 2026 | Tax withholding | −221 | $124.97 | $27.62K | 8,319 |
| Olivier Loeillot Chief Executive Officer, Director | Mar 2, 2026 | Tax withholding | −1,610 | $124.97 | $201.20K | 33,944 |
| Ralf Kuriyel Senior VP, R&D | Mar 2, 2026 | Tax withholding | −923 | $124.97 | $115.35K | 14,695 |
| James Bylund Chief Operating Officer | Mar 2, 2026 | Tax withholding | −2,433 | $124.97 | $304.05K | 17,609 |
| Jason K. Garland CFO | Feb 27, 2026 | Tax withholding | −327 | $128.73 | $42.09K | 13,056 |
| Olivier Loeillot Chief Executive Officer, Director | Feb 27, 2026 | Tax withholding | −344 | $128.73 | $44.28K | 35,554 |
| Ralf Kuriyel Senior VP, R&D | Feb 27, 2026 | Tax withholding | −444 | $128.73 | $57.16K | 15,618 |
| James Bylund Chief Operating Officer | Feb 27, 2026 | Tax withholding | −1,478 | $128.73 | $190.26K | 20,042 |
| Brian Robb Douglass CHIEF PRODUCT OFFICER | Dec 31, 2025 | Award | +2,288 | – | – | 8,540 |
| Karen A. Dawes Director | Dec 17, 2025 | Sale | −275 | $161.00 | $44.28K | 91,821 |
| Glenn P. Muir Director | Dec 16, 2025 | Option exercise | +3,366 | $26.12 | $87.92K | 36,622 |
| Anthony Hunt Director | Dec 4, 2025 | Other | −2,000 | – | – | 98,959 |
| Olivier Loeillot Chief Executive Officer, Director | Nov 25, 2025 | Sale(10b5-1 plan) | −7,041 | $170.00 | $1.20M | 35,898 |
| James Bylund Chief Operating Officer | Nov 18, 2025 | Sale | −2,191 | $151.21 | $331.30K | 21,520 |
| Anthony Hunt Director | Nov 13, 2025 | Option exercise | +2,952 | $33.87 | $99.98K | 83,695 |
| Anthony Hunt Director | Nov 13, 2025 | Sale | −1,956 | $157.11 | $307.31K | 80,743 |
| Anthony Hunt Director | Nov 13, 2025 | Sale | −5,737 | $156.22 | $896.23K | 82,699 |
| Anthony Hunt Director | Nov 13, 2025 | Sale | −3,000 | $155.45 | $466.35K | 88,436 |
| Anthony Hunt Director | Nov 13, 2025 | Sale | −2,500 | $154.32 | $385.80K | 91,436 |
| Anthony Hunt Director | Nov 13, 2025 | Sale | −2,923 | $153.14 | $447.63K | 93,936 |
| Anthony Hunt Director | Nov 13, 2025 | Sale | −2,100 | $152.17 | $319.56K | 96,859 |
| Anthony Hunt Director | Nov 13, 2025 | Sale | −1,784 | $151.01 | $269.40K | 98,959 |
| Anthony Hunt Director | Nov 12, 2025 | Sale(10b5-1 plan) | −11,096 | $158.01 | $1.75M | 101,207 |
| Anthony Hunt Director | Nov 12, 2025 | Sale(10b5-1 plan) | −464 | $158.51 | $73.55K | 100,743 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Olivier Loeillot Officer, Director | Oct 5, 2026 | 4,202 | $798.38K | Oct 5, 2026 | Stock Option Exercise |
| Olivier Loeillot Officer, Director | Oct 5, 2026 | 1,333 | $238.27K | Oct 5, 2026 | Restricted Stock Vesting |
| Olivier Loeillot Officer, Director | Sep 24, 2026 | 12,946 | $2.46M | Sep 24, 2026 | Stock Option Exercise |
| Olivier Loeillot Officer, Director | Sep 21, 2026 | 5,426 | $976.68K | Sep 21, 2026 | Stock Option Exercise |
| Olivier Loeillot Officer, Director | Sep 4, 2026 | 3,035 | $503.51K | Sep 4, 2026 | Restricted Stock Vesting |
| Olivier Loeillot Officer, Director | Aug 20, 2026 | 5,426 | $976.68K | Aug 20, 2026 | Stock Option Exercise |
| Jason K. Garland Officer | Jul 16, 2026 | 530 | $79.50K | Jul 16, 2026 | Restricted Stock Vesting |
| Jason K. Garland Officer | Jun 25, 2026 | 733 | $106.29K | Jun 25, 2026 | Restricted Stock Vesting |
| Olivier Loeillot Officer, Director | Apr 21, 2026 | 3,832 | $536.48K | Apr 21, 2026 | Restricted Stock Vesting |
| Karen A. Dawes Director | Dec 17, 2025 | 275 | $44.28K | Dec 17, 2025 | Stock Option Exercise |
| Olivier Loeillot Officer, Director | Nov 25, 2025 | 7,041 | $1.20M | Nov 25, 2025 | Restricted Stock Vesting |
| James Bylund Officer | Nov 18, 2025 | 2,191 | $331.30K | Nov 18, 2025 | Restricted Stock Vesting |
| Anthony Hunt Director | Nov 13, 2025 | 20,000 | $3.09M | Nov 13, 2025 | Stock Option Exercise |
| Anthony Hunt Director | Nov 12, 2025 | 25,000 | $3.92M | Nov 12, 2025 | Option Granted - 03/01/2018 |
| Anthony Hunt Director | Sep 10, 2025 | 29,111 | $3.51M | Sep 10, 2025 | Restricted Stock Vesting |